Optiver Holding
JSPR icon

Optiver Holding’s Jasper Therapeutics JSPR Stock Holding History

Optiver Holding’s Portfolio JSPR Stock Details JSPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$6 – 2939
2026
Q1 		$6 Hold
7
– – ﹤0.01% 2280
2025
Q4 		$13 Buy
7
+1
+17% +$2 ﹤0.01% 2423
2025
Q3 		$14 Buy
+6
New +$18 ﹤0.01% 2649

Other funds holding JSPR

VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Optiver Holding's JSPR Position: Q2 2026 in Review

Optiver Holding sold out of Jasper Therapeutics (JSPR) in Q2 2026, closing a stake of 7 shares — an estimated $6 sold.

Optiver Holding first reported a position in JSPR in Q3 2025 and held it in 3 quarters. The position peaked at $14 in Q3 2025. 45 funds tracked by Wall St. Rank hold JSPR as of Q2 2026.

  • Optiver Holding reported no remaining Jasper Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Optiver Holding sold 7 Jasper Therapeutics shares in Q2 2026, an estimated $6.
  • Optiver Holding first reported a position in Jasper Therapeutics in Q3 2025 and held it in 3 quarters.
  • Optiver Holding's Jasper Therapeutics position peaked at $14 in Q3 2025.
  • 45 funds tracked by Wall St. Rank held Jasper Therapeutics as of Q2 2026.

Based on Optiver Holding's 13F filing for Q2 2026, filed 12 Aug 2026.